Ergoteles’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Ergoteles’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-400,000	Closed	-$740K	–	1714
2023 Q1	$740K	Buy	+400,000	New	+$495K	0.03%	604

Other funds holding JNCE

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Ergoteles's JNCE Position: Q2 2023 in Review

Ergoteles sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 400,000 shares — an estimated $740K sold.

Ergoteles first reported a position in JNCE in Q1 2023 and held it in 1 quarter. The position peaked at $740K in Q1 2023. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

Ergoteles reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Ergoteles sold 400,000 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $740K.
Ergoteles first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
Ergoteles's Jounce Therapeutics, Inc. Common Stock position peaked at $740K in Q1 2023.
1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.